北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 感染疾病科  > 期刊论文
学科主题: 临床医学
题名:
Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon
作者: Hou, Feng-Qin1; Song, Liu-Wei2; Yuan, Quan2; Fang, Lin-Lin2; Ge, Sheng-Xiang2; Zhang, Jun2; Sheng, Ji-Fang3; Xie, Dong-Ying4; Shang, Jia5; Wu, Shu-Huan6; Sun, Yong-Tao7; Wei, Shao-Feng8; Wang, Mao-Rong9; Wan, Mo-Bin10; Jia, Ji-Dong11; Luo, Guang-Han12; Tang, Hong13; Li, Shu-Chen14; Niu, Jun-Qi15; Zhou, Wei-dong16; Sun, Li16; Xia, Ning-Shao2; Wang, Gui-Qiang1
关键词: quantitative anti-HBc ; chronic hepatitis B ; PEG-IFN treatment ; treatment response prediction ; pretreatment biomarker
刊名: THERANOSTICS
发表日期: 2015
DOI: 10.7150/thno.10636
卷: 5, 期:3, 页:218-226
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Medicine, Research & Experimental
研究领域[WOS]: Research & Experimental Medicine
关键词[WOS]: VIRUS INFECTION ; ANTIGEN ; LAMIVUDINE ; THERAPY ; SEROCONVERSION ; COMBINATION
英文摘要:

A recent study revealed that quantitative hepatitis B core antibody (qAnti-HBc) level could serve as a novel marker for predicting treatment response. In the present study, we further investigated the predictive value of qAnti-HBc level in HBeAg-positive patients undergoing PEG-IFN therapy. A total of 140 HBeAg-positive patients who underwent PEG-IFN therapy for 48 weeks and follow-up for 24 weeks were enrolled in this study. Serum samples were taken every 12 weeks post-treatment. The predictive value of the baseline qAnti-HBc level for treatment response was evaluated. Patients were further divided into 2 groups according to the baseline qAnti-HBc level, and the response rate was compared. Additionally, the kinetics of the virological and biochemical parameters were analyzed. Patients who achieved response had a significantly higher baseline qAnti-HBc level (serological response [SR], 4.52 +/- 0.36 vs. 4.19 +/- 0.58, p=0.001; virological response [VR], 4.53 +/- 0.35 vs. 4.22 +/- 0.57, p=0.005; combined response [CR], 4.50 +/- 0.36 vs. 4.22 +/- 0.58, p=0.009)). Baseline qAnti-HBc was the only parameter that was independently correlated with SR (p=0.008), VR (p=0.010) and CR(p=0.019). Patients with baseline qAnti-HBc levels >= 30,000 IU/mL had significantly higher response rates, more HBV DNA suppression, and better hepatitis control in PEG-IFN treatment. In conclusion, qAnti-HBc level may be a novel biomarker for predicting treatment response in HBeAg-positive patients receiving PEG-IFN therapy.

语种: 英语
所属项目编号: 30925030 ; 81371819 ; 2012ZX10002005 ; 2011ZX09101-008-06 ; 2012ZX10002006 ; 2013ZX10002005 ; D121100003912002
项目资助者: National Science Fund ; Technological Major Project ; Beijing Scientific &amp ; Technological Project
WOS记录号: WOS:000345207600001
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/52449
Appears in Collections:北京大学第一临床医学院_感染疾病科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Henan Prov Peoples Hosp, Dept Infect Dis, Zhengzhou, Peoples R China
2.PLA 81st Hosp, Dept Infect Dis, Nanjing, Jiangsu, Peoples R China
3.Peking Univ, Hosp 1, Ctr Liver Dis, Dept Infect Dis, Beijing 100871, Peoples R China
4.Xiamen Univ, Sch Publ Hlth, Natl Inst Diagnost & Vaccine Dev Infect Dis, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen, Peoples R China
5.Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Infect Dis, Hangzhou 310003, Zhejiang, Peoples R China
6.Sun Yat Sen Univ, Affiliated Hosp 3, Dept Infect Dis, Guangzhou 510275, Guangdong, Peoples R China
7.Zhengzhou Univ, Affiliated Hosp 1, Dept Infect Dis, Zhengzhou 450052, Peoples R China
8.Fourth Mil Med Univ, Tang Du Hosp, Dept Infect Dis, Xian 710032, Peoples R China
9.Anhui Med Univ, Affiliated Hosp 1, Dept Infect Dis, Hefei, Peoples R China
10.Second Mil Med Univ, Changhai Hosp, Dept Infect Dis, Shanghai, Peoples R China
11.Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Beijing, Peoples R China
12.Guangxi Med Univ, Affiliated Hosp 1, Dept Infect Dis, Nanning, Peoples R China
13.Sichuan Univ, West China Hosp, Ctr Infect Dis, Chengdu 610064, Peoples R China
14.Harbin Med Univ, Affiliated Hosp 2, Dept Infect Dis, Harbin, Peoples R China
15.Changchun Univ, Affiliated Hosp 1, Ctr Liver Dis, Changchun, Peoples R China
16.Xiamen Amoytop Biotech Co Ltd, Xiamen, Peoples R China

Recommended Citation:
Hou, Feng-Qin,Song, Liu-Wei,Yuan, Quan,et al. Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon[J]. THERANOSTICS,2015,5(3):218-226.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Hou, Feng-Qin]'s Articles
[Song, Liu-Wei]'s Articles
[Yuan, Quan]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Hou, Feng-Qin]‘s Articles
[Song, Liu-Wei]‘s Articles
[Yuan, Quan]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace